Search

everythinglearnresearchcommunity

for

Search:↓

The new drug delivery system effectively targets lung cancer cells.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

The woman was diagnosed with systemic lupus erythematosus (SLE) after initial misdiagnosis and improved with proper treatment.

Tumor cell adhesion is linked to higher risk of SLN metastasis and melanoma recurrence, and a model including these factors predicts these outcomes better than one with just clinical data.

New therapies like JAK inhibitors and stem cells show promise in treating vitiligo.

Thoracic medial branch block may be a simpler and effective alternative to thoracic vertebroplasty for pain management.

The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.

Ruxolitinib treatment may cause eyelash growth.

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

The muscle damage was caused by T-cell large granular lymphocytic leukemia, not dermatomyositis.

Stopping methotrexate might reverse lymphoma-like conditions in some patients.

The antibody 005-C04 blocks prolactin receptors, causing reversible infertility, impaired lactation, and hair regrowth in female mice.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

Nail changes from immunotherapy can be managed without stopping cancer treatment.

COVID-19 vaccination may trigger recurrence of cutaneous T-cell lymphoma in some patients.

Supplemental testosterone may lower liver cancer risk in hepatitis C patients.

New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.

Baricitinib successfully treated myasthenia gravis and alopecia in a patient.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

Oclacitinib maleate successfully treated alopecia in Andean bears.

Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Flow cytometry was effective in diagnosing metastatic breast cancer in a bone marrow sample.

Ritlecitinib is safe and may effectively treat alopecia areata.

Vinblastine and its metabolites may cause nausea and hair loss by binding to specific receptors and could lead to better chemotherapy drugs with fewer side effects.

Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.

JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.